6,052 Shares in Boston Scientific Co. (NYSE:BSX) Acquired by Radnor Capital Management LLC

Radnor Capital Management LLC purchased a new stake in Boston Scientific Co. (NYSE:BSX - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 6,052 shares of the medical equipment provider's stock, valued at approximately $507,000.

A number of other institutional investors have also made changes to their positions in the business. Norden Group LLC bought a new stake in Boston Scientific during the 1st quarter worth about $576,000. Csenge Advisory Group bought a new stake in Boston Scientific during the 1st quarter worth about $246,000. Advisory Alpha LLC bought a new stake in Boston Scientific during the 1st quarter worth about $369,000. Manchester Capital Management LLC raised its holdings in Boston Scientific by 6.8% during the 1st quarter. Manchester Capital Management LLC now owns 7,723 shares of the medical equipment provider's stock worth $529,000 after purchasing an additional 491 shares during the last quarter. Finally, Empirical Finance LLC raised its holdings in Boston Scientific by 3.6% during the 1st quarter. Empirical Finance LLC now owns 51,280 shares of the medical equipment provider's stock worth $3,512,000 after purchasing an additional 1,786 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $85.00, for a total value of $11,264,795.00. Following the completion of the sale, the executive vice president now owns 160,467 shares in the company, valued at $13,639,695. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.86, for a total value of $585,594.38. Following the sale, the executive vice president now owns 34,748 shares in the company, valued at approximately $2,913,967.28. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 132,527 shares of Boston Scientific stock in a transaction on Monday, October 7th. The stock was sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the transaction, the executive vice president now directly owns 160,467 shares of the company's stock, valued at approximately $13,639,695. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 309,270 shares of company stock valued at $26,196,718 in the last 90 days. 0.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

BSX has been the subject of several recent research reports. Stifel Nicolaus boosted their price objective on Boston Scientific from $85.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, October 18th. Mizuho boosted their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an "outperform" rating in a research report on Thursday, October 24th. Sanford C. Bernstein lifted their price objective on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an "outperform" rating in a research note on Thursday, October 24th. Needham & Company LLC restated a "hold" rating on shares of Boston Scientific in a report on Thursday, October 31st. Finally, StockNews.com lowered shares of Boston Scientific from a "buy" rating to a "hold" rating in a report on Monday. Four research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Boston Scientific currently has an average rating of "Moderate Buy" and a consensus price target of $93.39.

Boston Scientific Stock Up 0.5 %

BSX traded up $0.40 during trading hours on Thursday, hitting $86.84. 2,024,119 shares of the company's stock were exchanged, compared to its average volume of 6,082,933. The stock has a market cap of $127.88 billion, a price-to-earnings ratio of 71.42, a PEG ratio of 2.46 and a beta of 0.79. Boston Scientific Co. has a 1-year low of $50.84 and a 1-year high of $88.79. The stock's 50-day moving average is $84.35 and its two-hundred day moving average is $78.74. The company has a quick ratio of 1.14, a current ratio of 1.61 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.04. Boston Scientific had a return on equity of 17.41% and a net margin of 11.26%. The company had revenue of $4.21 billion during the quarter, compared to analysts' expectations of $4.04 billion. During the same quarter last year, the company earned $0.50 EPS. Boston Scientific's revenue for the quarter was up 19.3% compared to the same quarter last year. Sell-side analysts predict that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.